Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 27;14(1):45. doi: 10.3390/pharmaceutics14010045

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effect of MET+SM therapy combination on the relative mRNA expression of (A) hepatic genes involved in lipid metabolism, (B) Nrf2, (C) Scd-1, and (D) D9-desaturase index genes. Values are expressed as means ± SEM; n = 6 for HHTg/C, n = 7 for HHTg/MET, n = 8 for HHTg/MET+SM; ** p < 0.01, *** p < 0.001 probability reflecting the effect of MET monotherapy vs. the control group without treatment; ^† p < 0.05, ^†† p < 0.01, ^††† p < 0.001 probability reflecting the effect of MET therapy vs. MET+SM combination therapy.

Effect of MET+SM therapy combination on the relative mRNA expression of (A) hepatic genes involved in lipid metabolism, (B) Nrf2, (C) Scd-1, and (D) D9-desaturase index genes. Values are expressed as means ± SEM; n = 6 for HHTg/C, n = 7 for HHTg/MET, n = 8 for HHTg/MET+SM; ** p < 0.01, *** p < 0.001 probability reflecting the effect of MET monotherapy vs. the control group without treatment; ^† p < 0.05, ^†† p < 0.01, ^††† p < 0.001 probability reflecting the effect of MET therapy vs. MET+SM combination therapy.